A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease (MCI to Mild Dementia Due to AD)
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease (MCI to Mild Dementia Due to AD)
The purpose of this study is to assess the efficacy and safety of trontinemab in participants with early symptomatic Alzheimer's disease (AD) (mild cognitive impairment [MCI] to mild dementia due to AD).
Inclusion Criteria:
Exclusion Criteria:
global-roche-genentech-trials@gene.com888-662-6728
Columbus, Georgia 31904, United States
CABA, C1199ABA, Argentina
North YORK, Ontario M6A 2E1, Canada
Shanghai, Shanghai Municipality 200127, China
Beijing, 100050, China
Shanghai, 200233, China
Le Kremlin Bicétre Cedex, 94275, France
Bad Homburg, 61348, Germany
Bayreuth, 95445, Germany
Erbach/Odenwald, 64711, Germany
Freiburg im Breisgau, 79106, Germany
Steglitz, 12163, Germany
Meguro-Ku, 153-0051, Japan
Tokyo, 190-8531, Japan
Krakow, 31-505, Poland
Lublin, 20-410, Poland
Wroc?aw, 53-659, Poland
North Dist., 40447, Taiwan